vs
Side-by-side financial comparison of Industrial Logistics Properties Trust (ILPT) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $113.9M, roughly 1.6× Industrial Logistics Properties Trust). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -1.6%, a 3.2% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 3.1%). Over the past eight quarters, Industrial Logistics Properties Trust's revenue compounded faster (0.7% CAGR vs -0.2%).
Industrial Logistics Properties Trust is a real estate investment trust that owns and operates a portfolio of industrial and logistics real estate assets primarily across the United States. Its holdings include distribution centers, warehouses, and last-mile delivery properties, serving e-commerce, retail, manufacturing and supply chain operators to meet their storage and logistics operation needs.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ILPT vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $113.9M | $177.4M |
| Net Profit | $-1.8M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | -22.1% | 3.9% |
| Net Margin | -1.6% | 1.6% |
| Revenue YoY | 3.1% | 5.0% |
| Net Profit YoY | 92.6% | — |
| EPS (diluted) | $-0.02 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $113.9M | $196.9M | ||
| Q3 25 | $110.9M | $179.5M | ||
| Q2 25 | $112.1M | $181.1M | ||
| Q1 25 | $111.9M | $168.9M | ||
| Q4 24 | $110.5M | $187.3M | ||
| Q3 24 | $108.9M | $168.6M | ||
| Q2 24 | $110.6M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $-21.6M | $5.4M | ||
| Q2 25 | $-21.3M | $-4.8M | ||
| Q1 25 | $-21.5M | $4.8M | ||
| Q4 24 | $-24.1M | — | ||
| Q3 24 | $-25.0M | $-143.5M | ||
| Q2 24 | $-23.2M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -22.1% | 1.2% | ||
| Q3 25 | -29.4% | 3.5% | ||
| Q2 25 | -30.8% | 4.7% | ||
| Q1 25 | -26.9% | 1.2% | ||
| Q4 24 | -31.1% | 13.2% | ||
| Q3 24 | -33.5% | -82.8% | ||
| Q2 24 | -32.4% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -1.6% | — | ||
| Q3 25 | -19.4% | 3.0% | ||
| Q2 25 | -19.0% | -2.7% | ||
| Q1 25 | -19.2% | 2.8% | ||
| Q4 24 | -21.8% | — | ||
| Q3 24 | -22.9% | -85.1% | ||
| Q2 24 | -20.9% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.02 | $0.05 | ||
| Q3 25 | $-0.33 | $0.12 | ||
| Q2 25 | $-0.32 | $-0.11 | ||
| Q1 25 | $-0.33 | $0.10 | ||
| Q4 24 | $-0.37 | $0.38 | ||
| Q3 24 | $-0.38 | $-3.11 | ||
| Q2 24 | $-0.35 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $94.8M | $144.3M |
| Total DebtLower is stronger | $4.2B | — |
| Stockholders' EquityBook value | $489.7M | $653.9M |
| Total Assets | $5.2B | $1.2B |
| Debt / EquityLower = less leverage | 8.56× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $94.8M | $238.4M | ||
| Q3 25 | $83.2M | $246.3M | ||
| Q2 25 | $58.6M | $445.9M | ||
| Q1 25 | $108.0M | $493.6M | ||
| Q4 24 | $131.7M | $484.6M | ||
| Q3 24 | $153.9M | $453.8M | ||
| Q2 24 | $146.2M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $4.2B | $372.2M | ||
| Q3 25 | $4.2B | $376.7M | ||
| Q2 25 | $4.2B | $580.5M | ||
| Q1 25 | $4.3B | $583.4M | ||
| Q4 24 | $4.3B | $585.3M | ||
| Q3 24 | $4.3B | — | ||
| Q2 24 | $4.3B | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $489.7M | $693.1M | ||
| Q3 25 | $494.1M | $727.2M | ||
| Q2 25 | $519.1M | $757.8M | ||
| Q1 25 | $539.5M | $798.5M | ||
| Q4 24 | $562.0M | $778.3M | ||
| Q3 24 | $585.9M | $749.6M | ||
| Q2 24 | $618.3M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $5.2B | $1.3B | ||
| Q3 25 | $5.2B | $1.3B | ||
| Q2 25 | $5.2B | $1.5B | ||
| Q1 25 | $5.4B | $1.6B | ||
| Q4 24 | $5.4B | $1.6B | ||
| Q3 24 | $5.5B | $1.5B | ||
| Q2 24 | $5.5B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 8.56× | 0.54× | ||
| Q3 25 | 8.49× | 0.52× | ||
| Q2 25 | 8.09× | 0.77× | ||
| Q1 25 | 7.96× | 0.73× | ||
| Q4 24 | 7.65× | 0.75× | ||
| Q3 24 | 7.35× | — | ||
| Q2 24 | 6.96× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.7M | — |
| Free Cash FlowOCF − Capex | $42.0M | — |
| FCF MarginFCF / Revenue | 36.9% | — |
| Capex IntensityCapex / Revenue | 16.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $79.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $60.7M | $43.7M | ||
| Q3 25 | $22.7M | $60.8M | ||
| Q2 25 | $18.4M | $12.0M | ||
| Q1 25 | $11.4M | $35.5M | ||
| Q4 24 | $2.0M | $33.1M | ||
| Q3 24 | $-3.4M | $53.9M | ||
| Q2 24 | $10.8M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $42.0M | $43.5M | ||
| Q3 25 | $17.6M | $57.0M | ||
| Q2 25 | $15.2M | $9.3M | ||
| Q1 25 | $5.0M | $26.9M | ||
| Q4 24 | $-3.7M | $31.0M | ||
| Q3 24 | $-5.9M | $49.8M | ||
| Q2 24 | $9.4M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 36.9% | 22.1% | ||
| Q3 25 | 15.9% | 31.7% | ||
| Q2 25 | 13.5% | 5.1% | ||
| Q1 25 | 4.5% | 15.9% | ||
| Q4 24 | -3.4% | 16.6% | ||
| Q3 24 | -5.5% | 29.6% | ||
| Q2 24 | 8.5% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 16.4% | 0.1% | ||
| Q3 25 | 4.6% | 2.2% | ||
| Q2 25 | 2.9% | 1.5% | ||
| Q1 25 | 5.7% | 5.1% | ||
| Q4 24 | 5.2% | 1.1% | ||
| Q3 24 | 2.3% | 2.4% | ||
| Q2 24 | 1.3% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ILPT
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
